XTL Biopharmaceuticals Ltd. Sponsored ADR (XTLB) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
XTL Biopharmaceuticals Ltd. has entered into a settlement agreement involving an adjustment of American Depositary Shares and warrants with its subsidiary, The Social Proxy Ltd. The resolution saw the return of over 372 million ordinary shares to XTL’s treasury. XTL continues to explore strategic collaborations in the Lupus treatment space while expanding its portfolio.
For further insights into XTLB stock, check out TipRanks’ Stock Analysis page.
